Results 221 to 230 of about 1,069,910 (348)

Analysis of Single Particles of Amyloid Beta and α‐Synuclein With Seeded Amplification for the Diagnosis of Alzheimer's and Parkinson's Disease

open access: yesBiotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD), are characterized by the pathological aggregation of specific proteins such as amyloid beta (Aβ) and α‐synuclein, respectively. Early detection of these protein aggregates in biological fluids could facilitate timely diagnosis and therapeutic ...
Alexandra Dybala   +4 more
wiley   +1 more source

Relationship Between Clozapine-Induced Inflammation and Eosinophilia: A Retrospective Cohort Study. [PDF]

open access: yesSchizophr Bull
Kikuchi Y   +6 more
europepmc   +1 more source

Asymptomatic murmurs [PDF]

open access: yesPostgraduate Medical Journal, 1998
openaire   +2 more sources

COVID-19: PCR screening of asymptomatic health-care workers at London hospital

open access: yesThe Lancet, 2020
T. Treibel   +9 more
semanticscholar   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova   +5 more
wiley   +1 more source

Asymptomatic patients as a source of COVID-19 infections: A systematic review and meta-analysis

open access: yesInternational Journal of Infectious Diseases, 2020
A. Kronbichler   +5 more
semanticscholar   +1 more source

Long‐term impact of Elexacaftor/Tezacaftor/ivacaftor on pulmonary, nutritional and metabolic outcomes in homozygous F508del cystic fibrosis patients: A real‐world cohort study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Elexacaftor/tezacaftor/ivacaftor (ETI) has markedly improved cystic fibrosis (CF) outcomes. However, its long‐term impact on nutrition, metabolism and liver health remains underexplored. We assessed 30‐month changes in pulmonary, nutritional, metabolic and inflammatory markers in people with CF (PwCF) homozygous for F508del.
Nicola Perrotta   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy